Digestive Diseases and Sciences

, Volume 52, Issue 9, pp 2359–2367

The Effects of Rosiglitazone, Metformin, and Diet with Exercise in Nonalcoholic Fatty Liver Disease

  • Filiz Akyüz
  • Kadir Demir
  • Sadakat Özdil
  • Nevzat Aksoy
  • Şule Poturoğlu
  • Duygu İbrişim
  • Sabahattin Kaymakoğlu
  • Fatih Beşışık
  • Güngör Boztaş
  • Yılmaz Çakaloğlu
  • Zeynel Mungan
  • Uğur Çevikbaş
  • Atilla Ökten
Original Paper

Abstract

Our aım was to evaluate effects of metformin, rosiglitazone, and diet with exercise in nonalcoholic fatty liver disease. Forty-seven patients (mean age, 44±10 years; 17 female) whose ALT levels had been high for at least 6 months and with hepatosteatosis detected by liver biopsy and/or USG were enrolled in this study. Of these, 12 were treated with 850 mg/day metformin (group 1), 11 with 4 mg/day rosiglitazone (group 2), and 24 with diet and exercise (group 3) for 1 year. ALT normalization at months 6 and 12 was accepted as treatment response. Liver biopsy was performed in all patients in groups 1 and 2 before treatment and 12 patients (4 in group 1, 8 in group 2) after treatment; but in group 3 it was performed only in patients who approved this procedure (12 patients). Body mass index did not change in groups 1 and 2, but it decreased significantly in group 3 (30±3 to 28±2 kg/m2) at month 12. Treatment response rate was 33.3, 54.5, and 54.2% in groups 1, 2, and 3, respectively, at month 6. This rate was 22.2, 37.5, and 41.2 in groups 1, 2, and 3, respectively, at month 12. Rate of steatosis and stage of fibrosis did not change after treatment. Diet with exercise seems to be superior to metformin and rosiglitazone. Decreasing treatment response at month 12 compared to month 6 may be due to fluctuations of ALT levels. Treatment response should be evalulated histologically.

Keywords

Nonalcoholic fatty liver disease Treatment 

References

  1. 1.
    Ludwig J, Viggiano TR, McGill DB, Oh BJ (1980) Nonalcoholic steatohepatitis. Mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55:434–438Google Scholar
  2. 2.
    Day CP, James OFW (1998) Hepatic steatosis: innocent bystander or guilty party? Hepatology 27:1463–1466PubMedCrossRefGoogle Scholar
  3. 3.
    Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ (1999) Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 29:664–669PubMedCrossRefGoogle Scholar
  4. 4.
    Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M (2002) Expanding the natural history of non-alcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123:134–140PubMedCrossRefGoogle Scholar
  5. 5.
    Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ (1999) Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116:1413–1419PubMedCrossRefGoogle Scholar
  6. 6.
    Drenick EJ, Simmons F, Murphy JF (1970) Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small bowel bypass. N Engl J Med 282:829–834PubMedCrossRefGoogle Scholar
  7. 7.
    Andersen T, Gluud C, Franzmann MB, Christoffersen P (1991) Hepatic effects of dietary weight loss in morbidly obese patients. J Hepatol 12:224–229PubMedCrossRefGoogle Scholar
  8. 8.
    Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, Torimura T, Inuzuka S, Sata M, Tanikawa K (1997) Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 27:103–107PubMedCrossRefGoogle Scholar
  9. 9.
    Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, Rakela J, McGill DB (1996) Ursodeoxycholic acid or clofibrate in the treatment of non-alcoholic-induced steatohepatitis: A pilot study. Hepatology 23:1464–1467PubMedCrossRefGoogle Scholar
  10. 10.
    Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenky-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167–1174PubMedCrossRefGoogle Scholar
  11. 11.
    Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N (2001) Metformin in nonalcoholic steatohepatitis. Lancet 358:893–894PubMedCrossRefGoogle Scholar
  12. 12.
    Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A, Yesilova Z, Gulsen M, Dagalp K (2004) Metformin in the treatment of patients with nonalcoholic steatohepatitis. Aliment Pharmacol Ther 19:537–544PubMedCrossRefGoogle Scholar
  13. 13.
    Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL (2001) A pilot study of thiazolidinedione, troglitazone, in non-alcoholic steatohepatitis. Am J Gastroenterol 96:519–525PubMedCrossRefGoogle Scholar
  14. 14.
    Mayerson, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, Enocksson S, Inzucchi SE, Shulman GI, Petersen KF (2002) The effects of rosiglitazone on insulin sensitivity, lipolysis and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51:797–802PubMedCrossRefGoogle Scholar
  15. 15.
    Tetri-Neuschwander BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR (2003) Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone. Hepatology 38:1008–1017Google Scholar
  16. 16.
    Day CP (2003) Management future targets in NAFLD. In ``Non Alcoholic Fatty Liver Disease'' President's premeeting syllabus. 38th annual meeting of the European Association for the study of the liver; Tozun N, Avsar E (eds). Istanbul, A & G Agency, pp 58–65.Google Scholar
  17. 17.
    Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, Doo E, Ghany M, Premkumar A, Park Y, Liang TJ, Yanovski JA, Kleiner DE, Hoofnagle JH (2004) A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39:188–196PubMedCrossRefGoogle Scholar
  18. 18.
    Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J (2002) NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 35:373–379PubMedCrossRefGoogle Scholar
  19. 19.
    Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR (1999) Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94:2467–2474PubMedCrossRefGoogle Scholar
  20. 20.
    Harrison SA, Torgerson S, Hayashi PH, Ward J, Schenker S (2003) Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 98:2485–2490PubMedCrossRefGoogle Scholar
  21. 21.
    Kadayıfcı A (2003) Nonalcoholic steatoepatitis: Role of leptin in pathogenesis and benefits of metformin in treatment. Am J Gastronterol 98:2330Google Scholar
  22. 22.
    Lin HZ, Yang SQ (2003) Current biochemical studies of nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) suggest a new therapeutic approach. Am J Gastroenterol 98:495–499CrossRefGoogle Scholar
  23. 23.
    Fan JG, Zhong L, Xu ZJ, Tia LY, Ding XD, Li MS, Wang GL (2003) Effects of low calori diet on steatohepatitis in rats with obesity and hyperlipidemia. World J Gastroenterol 9:2045–2049PubMedGoogle Scholar
  24. 24.
    Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA (1994) Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 107:1103–1109PubMedGoogle Scholar
  25. 25.
    Angulo P, Keach JC, Batts KP, Lindor KD (1999) Independent predictors of liver fibrosis in patients with non-alcoholic steatohepatitis. Hepatology 30:1356–1362PubMedCrossRefGoogle Scholar
  26. 26.
    Ipekci SH, Basaranoglu M, Sonsuz A (2003) The fluctuation of serum levels of aminotransferase in patients with nonalcoholic steatohepatitis. J Clin Gastroenterol 18:1220–1221Google Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Filiz Akyüz
    • 1
    • 3
  • Kadir Demir
    • 1
  • Sadakat Özdil
    • 1
  • Nevzat Aksoy
    • 1
  • Şule Poturoğlu
    • 1
  • Duygu İbrişim
    • 1
  • Sabahattin Kaymakoğlu
    • 1
  • Fatih Beşışık
    • 1
  • Güngör Boztaş
    • 1
  • Yılmaz Çakaloğlu
    • 1
  • Zeynel Mungan
    • 1
  • Uğur Çevikbaş
    • 2
  • Atilla Ökten
    • 1
  1. 1.Department of Gastroenterohepatology İstanbul Universityİstanbul Faculty of MedicineIstanbulTurkey
  2. 2.Department of Pathologyİstanbul University, İstanbul Faculty of MedicineIstanbulTurkey
  3. 3.Şakacı sok. BirlikİstanbulTurkey

Personalised recommendations